Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. / Niemann, Carsten U.; da Cunha-Bang, Caspar; Helleberg, Marie; Ostrowski, Sisse R.; Brieghel, Christian.

In: Blood, Vol. 140, No. 5, 2022, p. 445-450.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Niemann, CU, da Cunha-Bang, C, Helleberg, M, Ostrowski, SR & Brieghel, C 2022, 'Patients with CLL have a lower risk of death from COVID-19 in the Omicron era', Blood, vol. 140, no. 5, pp. 445-450. https://doi.org/10.1182/blood.2022016147

APA

Niemann, C. U., da Cunha-Bang, C., Helleberg, M., Ostrowski, S. R., & Brieghel, C. (2022). Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood, 140(5), 445-450. https://doi.org/10.1182/blood.2022016147

Vancouver

Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood. 2022;140(5):445-450. https://doi.org/10.1182/blood.2022016147

Author

Niemann, Carsten U. ; da Cunha-Bang, Caspar ; Helleberg, Marie ; Ostrowski, Sisse R. ; Brieghel, Christian. / Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. In: Blood. 2022 ; Vol. 140, No. 5. pp. 445-450.

Bibtex

@article{0bafafa90f61474499908f5603615b37,

title = "Patients with CLL have a lower risk of death from COVID-19 in the Omicron era",

abstract = "Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.",

author = "Niemann, {Carsten U.} and {da Cunha-Bang}, Caspar and Marie Helleberg and Ostrowski, {Sisse R.} and Christian Brieghel",

note = "Publisher Copyright: {\textcopyright} 2022 American Society of Hematology",

year = "2022",

doi = "10.1182/blood.2022016147",

language = "English",

volume = "140",

pages = "445--450",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

RIS

TY - JOUR

T1 - Patients with CLL have a lower risk of death from COVID-19 in the Omicron era

AU - Niemann, Carsten U.

AU - da Cunha-Bang, Caspar

AU - Helleberg, Marie

AU - Ostrowski, Sisse R.

AU - Brieghel, Christian

PY - 2022

Y1 - 2022

N2 - Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.

AB - Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and coronavirus disease 2019 (COVID-19) have high mortality rates. Infection with the Omicron variant has been described as a milder disease course in the general population. However, the outcome for immunocompromised patients has not previously been reported. In a cohort of patients with CLL tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at hospital test sites in the time periods before and after dominance of the Omicron variant, rates of hospitalizations and intensive care unit admissions declined significantly, whereas 30-day mortality remained as high as 23% in the period with dominance of the Omicron sublineage BA.2 variant. However, for a larger population-based cohort of patients with CLL (including the hospital cohort), 30-day mortality was 2%. Thus, patients with CLL with close hospital contacts and, in particular, those >70 years of age with 1 or more comorbidities should be considered for closer monitoring and preemptive antiviral therapy upon a positive SARS-CoV-2 test.

U2 - 10.1182/blood.2022016147

DO - 10.1182/blood.2022016147

M3 - Journal article

C2 - 35588468

AN - SCOPUS:85134745055

VL - 140

SP - 445

EP - 450

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -

ID: 323844906

Forskning